Bioventus Launches DUROLANE® for Osteoarthritis Patients in Taiwan
HOOFDDORP, THE NETHERLANDS--(Business Wire/Korea Newswire) January 5, 2016 -- Bioventus (www.bioventusglobal.com), a leader in orthobiologic solutions, today announced its entry into the patient care market in Taiwan with the launch of DUROLANE®, a single-injection joint-fluid osteoarthritis (OA) treatment based on a natural, safe and proven technology process called NASHA® which yields stabilized hyaluronic acid (HA).
Hyaluronic acid is a naturally occurring molecule that provides the lubrication and cushioning in a normal joint. In Taiwan, DUROLANE is indicated for the treatment of mild to moderate (OA) of the knee.
“The combination of a leading OA solution like DUROLANE and Taiwan’s robust economy gives Bioventus a terrific opportunity to establish itself and grow in this market,” said Tony Bihl, CEO, Bioventus. “Orthobiologic solutions from Bioventus are now available in six countries in the Asia Pacific region and we plan to build on this as we continue our international expansion.”
“In Taiwan, Bioventus will be working with Eulogiums, a sales and marketing leader with more than 20 years of experience in orthopaedics,” said Isabelle Levy-Unger, Managing Director International, for Canada, Latin America and Asia Pacific, Bioventus.
“The company’s market coverage, relationships with key opinion leaders, along with its keen understanding of markets and trends made it the natural choice to help us introduce DUROLANE to patients with knee OA,” she added.
“We believe that only knee OA products with superior quality can withstand in the competitive market in Taiwan and we have confidence that DUROLANE is the one,” said Kenny Liu, CEO, Eulogiums Co Ltd.
DUROLANE is available in Taiwan now and more information about the product can be found at www.durolane.com.
Bioventus LLC is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Bioventus has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
For more information, visit www.BioventusGlobal.com and follow the company on Twitter https://twitter.com/Bioventusglobal
DUROLANE - Indications
For the symptomatic treatment of mild to moderate knee osteoarthritis.
There are no known contraindications. You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/or stiffness at the injection site. Clinical effectiveness has been demonstrated out to six months but results may vary depending on various patient factors.
Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
DUROLANE and NASHA are registered trademarks of Galderma S.A.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160104006050/en/